APLT — Applied Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $56.45m
- -$22.95m
- $0.46m
- 14
- 15
- 44
- 13
Annual income statement for Applied Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 9.99 | 0.455 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 94.5 | 106 | 83 | 74.5 | 105 |
| Operating Profit | -94.5 | -106 | -83 | -64.5 | -104 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -94 | -106 | -82.5 | -120 | -106 |
| Net Income After Taxes | -94 | -106 | -82.5 | -120 | -106 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -94 | -106 | -82.5 | -120 | -106 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -94 | -106 | -82.5 | -120 | -106 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -4.28 | -4.12 | -2.18 | -1.42 | -0.757 |